Authors: Tatsuo Kanda Fumio Imazeki Ryosaku Azemoto Yutaka Yonemitsu Shigeru Mikami Kazuhiko Kita Motohide Takashi Masahiko Sunaga Shuang Wu Shingo Nakamoto Akinobu Tawada Makoto Arai Keizo Kato Yu Yoshida Yoshihiro Koma Keiichi Fujiwara Kenichi Fukai Noriaki Suzuki Osamu Yokosuka
Publish Date: 2011/05/22
Volume: 56, Issue: 11, Pages: 3335-3342
Abstract
Between 2006 and 2009 among 147 patients with HCV genotype 2infection in Chiba Prefecture 138 consecutive patients were finally enrolled Twentyone 97 and 20 patients were treated with PEGIFNalfa 2b plus RBV for 16 24 and 48 weeks respectively Epidemiological data and treatment outcomes were retrospectively evaluated HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v 20The overall SVR rate was 826 114 of 138 treatmentnaïve patients 864 89 of 103 patients with history of previous treatment 714 25 of 35 Patients treated for 16 24 and 48 weeks obtained SVR rates of 666 14 of 21 865 84 of 97 and 800 16 of 20 respectivelyThe SVR rates of PEGIFNalfa 2b plus RBV in Japanese patients were similar to those in previous studies Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks More precise patient selection will be needed to shorten the combination treatmentThis work was supported by grants for Scientific Research 21590829 from the Ministry of Education Culture Sports Science and Technology Japan TK and a grant from Chiba University Young ResearchOriented Faculty Member Development Program in Bioscience Areas TK
Keywords: